NTLA
Intellia Therapeutics Inc
NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY
$13.48
+8.32% today
Updated 2026-04-30
Market cap
$1.48B
P/E ratio
—
P/S ratio
21.87x
EPS (TTM)
$-3.81
Dividend yield
—
52W range
$7 – $28
Volume
5.1M
Intellia Therapeutics Inc (NTLA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.48M | $-1.76M | $36.11M | $-65.28M | $-61.26M | $-103.24M | $-49.91M | $-225.03M | $-333.29M | $-394.09M | $-348.88M | $-348.88M |
| Capital expenditures | $412500.00 | $2.55M | $6.17M | $10.09M | $6.36M | $6.79M | $3.58M | $12.76M | $58.39M | $13.98M | $5.78M | $5.78M |
| Depreciation | $4500.00 | $328000.00 | $1.10M | $2.99M | $4.46M | $5.59M | $6.31M | $6.89M | $7.57M | $8.98M | $10.29M | — |
| Stock-based comp | $462000.00 | $1.31M | $6.71M | $15.32M | $17.05M | $15.09M | $19.90M | $47.01M | $91.40M | $134.05M | $154.27M | $154.27M |
| Free cash flow | $-3.90M | $-4.32M | $29.94M | $-75.37M | $-67.61M | $-110.03M | $-53.50M | $-237.79M | $-391.68M | $-408.07M | $-354.66M | $-354.66M |
| Investing cash flow | $-862500.00 | $-2.55M | $-6.17M | $-10.09M | $-260.78M | $25.18M | $-214.49M | $-550.78M | $160.31M | $-31.35M | $125.57M | — |
| Financing cash flow | $19.11M | $70.29M | $167.30M | $142.98M | $40.22M | $76.43M | $371.78M | $736.69M | $582.96M | $130.32M | $185.75M | — |
| Dividends paid | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $197.25M | $67.61M | $-281.82M | $-1.63M | $107.38M | $-39.12M | $409.98M | — | — | — |